Reborna Biosciences focuses on innovative biotechnological solutions aimed at advancing healthcare through the development of novel therapies. The company specializes in harnessing the power of RNA-based technologies, particularly in the realm of gene editing and therapeutic applications. Their pipeline includes a range of products designed to address various diseases by utilizing RNA molecules to modulate gene expression, thereby offering potential treatments for conditions that currently lack effective therapies.

In addition to RNA technologies, Reborna Biosciences emphasizes the importance of precision medicine, tailoring treatments to individual patient profiles. Their scientific approach integrates advanced research methodologies and a deep understanding of molecular biology to create targeted therapies. This commitment to personalized medicine aims to enhance treatment efficacy and minimize side effects, ultimately improving patient outcomes in diverse therapeutic areas.

Japan

Reborna Biosciences is a Japan based startup company developing RNA-targeting small molecule drugs for rare genetic diseases.

Our proprietary screening method discovers orally available small molecules by reproducing the natural three-dimensional structure of RNA that exists in human body. Therefore, it can be expected to identify drug candidates having a higher extrapolation to clinical practice than the conventional screening method using artificially fragmented RNA (a form that does not exist in the body).

We are convinced that this unique technology will contribute to the development of therapeutic drugs with higher efficacy and fewer side effects.

Reborna Biosciences

Company Details